Abstract
Lone atrial fibrillation is a set of heterogeneous disorders grouped together due to our limited understanding of their pathophysiology. Rate control and rhythm control are two strategies used to treat atrial fibrillation but neither has shown improvement in mortality. Therefore, the goal of treatment in patients with lone atrial fibrillation is to improve health related quality of life. Anti-arrhythmic medications are not well studied in lone atrial fibrillation patient population in randomized controlled fashion. However, inferences can be made from trials that mainly included paroxysmal atrial fibrillation patients. Anti-arrhythmic medications are useful in maintenance of sinus rhythm and probably improve quality of life in lone atrial fibrillation.
Keywords: Atrial fibrillation, anti-arrhythmic drugs, healthcare related quality of life.
Current Pharmaceutical Design
Title:Utility of Anti-Arrhythmic Medications in ‘Lone Atrial Fibrillation’
Volume: 21 Issue: 5
Author(s): Ramanan Kumareswaran and Paul Dorian
Affiliation:
Keywords: Atrial fibrillation, anti-arrhythmic drugs, healthcare related quality of life.
Abstract: Lone atrial fibrillation is a set of heterogeneous disorders grouped together due to our limited understanding of their pathophysiology. Rate control and rhythm control are two strategies used to treat atrial fibrillation but neither has shown improvement in mortality. Therefore, the goal of treatment in patients with lone atrial fibrillation is to improve health related quality of life. Anti-arrhythmic medications are not well studied in lone atrial fibrillation patient population in randomized controlled fashion. However, inferences can be made from trials that mainly included paroxysmal atrial fibrillation patients. Anti-arrhythmic medications are useful in maintenance of sinus rhythm and probably improve quality of life in lone atrial fibrillation.
Export Options
About this article
Cite this article as:
Kumareswaran Ramanan and Dorian Paul, Utility of Anti-Arrhythmic Medications in ‘Lone Atrial Fibrillation’, Current Pharmaceutical Design 2015; 21 (5) . https://dx.doi.org/10.2174/1381612820666140825145357
DOI https://dx.doi.org/10.2174/1381612820666140825145357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Treatment of Fabry Disease: Current and Emerging Strategies
Current Pharmaceutical Biotechnology mTOR in Growth and Protection of Hypertrophying Myocardium
Cardiovascular & Hematological Agents in Medicinal Chemistry The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Possible Therapeutic Targets in Cardiac Myocyte Apoptosis
Current Pharmaceutical Design Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Structural and Electrical Remodeling: From Myocardial Cytology to Cardiodiabetology
Current Vascular Pharmacology Recent Patents in Cardiac Resynchronization Therapy
Recent Patents on Biomedical Engineering (Discontinued) Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology The Role of Calcium and the L-Type Calcium Channel in Pathological Remodeling of the Heart
Vascular Disease Prevention (Discontinued) The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes
Inflammation & Allergy - Drug Targets (Discontinued) Effect of a New Class of Compounds of the Group of Substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines on the Inflammatory and Cytokine Response in Experimental Myocardial Infarction
Current Vascular Pharmacology Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling
Current Pharmaceutical Design Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Oxidative Stress on Progenitor and Stem Cells in Cardiovascular Diseases
Current Pharmaceutical Biotechnology Ranolazine, a Partial Fatty Acid Oxidation Inhibitor, its Potential Benefit in Angina and Other Cardiovascular Disorders
Recent Patents on Cardiovascular Drug Discovery Usefulness of 5 Minutes <sup>123</sup>I-mIBG Scan in Parkinson’s Disease and Heart Failure
Current Radiopharmaceuticals Targeting the AMP-Activated Protein Kinase for the Treatment of Type 2 Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design